m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02711)
Name
PYRAZOLOPYRIDAZINE 2
Synonyms
PYRAZOLOPYRIDAZINE 2; pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
    Click to Show/Hide
Status
Investigative
Structure
Formula
C18H16N6O2
InChI
1S/C18H16N6O2/c1-25-16-6-5-12(10-17(16)26-2)22-18-19-9-7-14(23-18)13-11-21-24-15(13)4-3-8-20-24/h3-11H,1-2H3,(H,19,22,23)
InChIKey
AGAYQQLAAVQQLA-UHFFFAOYSA-N
PubChem CID
6539367
TTD Drug ID
D0O0VP
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cyclin-dependent kinase 2 (CDK2)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for PYRAZOLOPYRIDAZINE 2. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of PYRAZOLOPYRIDAZINE 2 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [1], [2]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for PYRAZOLOPYRIDAZINE 2. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PYRAZOLOPYRIDAZINE 2 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [2], [3]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for PYRAZOLOPYRIDAZINE 2. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PYRAZOLOPYRIDAZINE 2 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [1], [2]
Cyclin-dependent kinase 4 (CDK4)
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for PYRAZOLOPYRIDAZINE 2. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of PYRAZOLOPYRIDAZINE 2 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [4], [5]
Protein virilizer homolog (VIRMA)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for PYRAZOLOPYRIDAZINE 2. The Protein virilizer homolog (VIRMA) has potential in affecting the response of PYRAZOLOPYRIDAZINE 2 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [4], [5]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for PYRAZOLOPYRIDAZINE 2. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PYRAZOLOPYRIDAZINE 2 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). [3], [5]
Glycogen synthase kinase-3 beta (GSK-3B)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for PYRAZOLOPYRIDAZINE 2. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of PYRAZOLOPYRIDAZINE 2 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). [6], [7]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Glycogen synthase kinase-3 beta (GSK-3B) is a therapeutic target for PYRAZOLOPYRIDAZINE 2. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PYRAZOLOPYRIDAZINE 2 through regulating the expression of Glycogen synthase kinase-3 beta (GSK-3B). [7], [8]
References
Ref 1 FTO regulates adipogenesis by controlling cell cycle progression via m(6)A-YTHDF2 dependent mechanism. Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Oct;1863(10):1323-1330. doi: 10.1016/j.bbalip.2018.08.008. Epub 2018 Aug 13.
Ref 2 Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. J Med Chem. 2005 Sep 8;48(18):5639-43. doi: 10.1021/jm050392q.
Ref 3 YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nat Commun. 2019 Oct 25;10(1):4892. doi: 10.1038/s41467-019-12801-6.
Ref 4 Identification of pathology-specific regulators of m(6)A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine. EPMA J. 2020 Jul 29;11(3):485-504. doi: 10.1007/s13167-020-00220-3. eCollection 2020 Sep.
Ref 5 Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem. 2001 Dec 20;44(26):4615-27. doi: 10.1021/jm0103256.
Ref 6 Vascular Smooth Muscle FTO Promotes Aortic Dissecting Aneurysms via m6A Modification of Klf5. Front Cardiovasc Med. 2020 Nov 20;7:592550. doi: 10.3389/fcvm.2020.592550. eCollection 2020.
Ref 7 Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71. doi: 10.1016/j.ejmech.2008.08.012. Epub 2008 Sep 16.
Ref 8 N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nat Commun. 2022 May 13;13(1):2672. doi: 10.1038/s41467-022-30217-7.